Arthritis
Results from two REMICADE studies presented at conference
Published in Cancer Weekly, November 16th, 2004
New data from the Active Controlled Study of Patients Receiving Infliximab for Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) trial show that 79% of rheumatoid arthritis patients treated with REMICADE (infliximab) plus methotrexate (REMICADE regimen) who began the study with no joint erosions, maintained an erosion-free state by developing no new joint erosions at 1 year compared with 58% of patients treated with methotrexate alone.
Additionally, in all patients, 64% of patients in the REMICADE treated groups experienced no worsening in joint erosion scores compared with 49% of patients receiving methotrexate alone. These new findings emerged from the ASPIRE...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2004-11-16)
More Articles from Cancer Weekly
- Brain Cancer
Angiogenic cytokines have diverse effects on astrocytoma neovascularization - Brain Cancer
Study blocks mechanism that lets brain tumors sidetrack immune response - Breast Cancer
Oncostatin M induces S100A9 gene expression in breast tumor cells - Glioblastoma
Recombinant anti-HER2/neu antibody causes tumor cell death - Prostate Cancer
Study to define maximum tolerated dose of INSM-18 in prostate cancer patients - AIDS/HIV Vaccine
Vaccine against HIV-1 B and E subtypes is safe and immunogenic - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
